

Date: 27 April 2022

Re: Freedom of Information Request
Ref: 112-2022

Thank you for your email dated the 1/4/2022, requesting information in relation to myelofibrosis.

The information that you require is as follows:

Q1. Does your trust treat myelofibrosis? If not, which other trust do you refer these patients to? [Yes](#)

Q2.

a) Please provide the total number of patients treated in the last 6 months (or the latest 6 months data you have available) for myelofibrosis (ICD10 code D47.4). [11 patients](#)

b) How many of these patients were above age 65? [7 patients](#)

Q3. How many myelofibrosis patients were treated in the past 6 months with Ruxolitinib? [8 patients](#)

Q4.

a) How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? [15 patients](#)

b) Of these patients, how many were treated in the past 6 months (or the latest 6 months data you have available) with:

- **Hydroxyurea [0](#)**
- **Fedratinib [0](#)**
- **Received No Treatment [0](#)**

Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?

- [A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 \(Dose Escalation of CPI-0610 in Patients with](#)

Haematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis). There are currently no participants at CCC taking part in this trial

- The UK Myeloproliferative Neoplasms Registry for Myelofibrosis. This study has just opened, no participants as yet

Should you require any further information please do not hesitate to contact me on the email address provided below.

Please remember to quote the reference number above in any future communications.

If you are dissatisfied with the handling of your request, you have the right to ask for this to be investigated internally.

If you are dissatisfied with the information you have received, you have the right to ask for an internal review.

Both processes will be handled in accordance with our Trust's Freedom of Information Policy and the Freedom of Information Act 2000.

Internal investigation and internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to: Freedom of Information Review, The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, Wirral, CH63 4JY

If you are not satisfied with the outcome of the internal investigation/review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

In order for us to ensure customer satisfaction and to monitor compliance with the Freedom of Information Act 2000, we would be grateful if you could take a couple of minutes to complete a short feedback form via the link below:

<https://www.surveymonkey.co.uk/r/H39RFMM>

Kind Regards,

The Information Governance Team
Contact Email: ccf-tr.foi@nhs.net